Novel inhalation devices for treatment of chronic obstructive pulmonary disease
https://doi.org/10.18093/0869-0189-2016-26-3-352-356
Abstract
The aim of this review was to introduce readers to technical characteristics and advantages of recently available inhalers used for treatment of chronic obstructive pulmonary disease. Such inhalation devices as Breezehaler, Ellipta, Genuair, NEXThaler, and Respimat were described in details in this article.
About the Authors
V. V. Arkhipov
I.M.Sechenov First Moscow State Medical University, Healthcare Ministry of Russia: 8, build. 2, Trubetskaya str., Moscow, 119991, Russia
Russian Federation
Russian Federation
MD, Professor at Department of Clinical Pharmacology, I.M.Sechenov First Moscow State Medical University, Healthcare Ministry of Russia; tel.: (495) 9155801
D. E. Arkhipova
I.M.Sechenov First Moscow State Medical University, Healthcare Ministry of Russia: 8, build. 2, Trubetskaya str., Moscow, 119991, Russia
Russian Federation
Russian Federation
PhD, Assistant Lecturer at Department of Clinical Pharmacology and Propaedeutics of Internal Diseases, I.M.Sechenov First Moscow State Medical University, Healthcare Ministry of Russia; tel.: (495) 9155801
N. B. Lazareva
I.M.Sechenov First Moscow State Medical University, Healthcare Ministry of Russia: 8, build. 2, Trubetskaya str., Moscow, 119991, Russia
Russian Federation
Russian Federation
MD, Professor at Department of Clinical Pharmacology, I.M.Sechenov First Moscow State Medical University, Healthcare Ministry of Russia; tel.: (495) 9155801
References
1. Laube B.L., Janssens H.M., de Jongh F.H. et al. What the pulmonary specialist should know about the new inhalation therapies. Eur. Respir. J. 2011; 37 (6): 1308–1331.
2. Rootmensen G.N., van Keimpema A.R., Jansen H.M., de Haan R.J. Predictors of incorrect inhalation technique in patients with asthma or COPD: a study using a validated videotaped scoring method. J. Aerosol. Med. Pulm. Drug Deliv. 2010; 23 (5): 323–328.
3. Pothirat C., Chaiwong W., Phetsuk N. et al. Evaluating inhaler use technique in COPD patients. Int. J. Chron. Obstruct. Pulm. Dis. 2015; 10: 1291–1298.
4. Alaboud A., Assi K.H., and Chrystyn H. In vitro characterization of the emitted dose from the foradil Aerolizer to identify the influence of inhalation flow, inhalation volume and the number of inhalations per dose. Respiratory Drug Delivery. 2012; 3: 803–806.
5. Azouz W., Chetcuti P., Hosker H.S. et al. The inhalation characteristics of patients when they use different dry powder inhalers. J. Aerosol. Med. Pulm. Drug Deliv. 2015; 28 (1): 35–42.
6. Usmani O.S., Biddiscombe M.F., Barnes P.J. Regional lung deposition and bronchodilator response as a function of beta2"agonist particle size. Am. J. Respir. Crit. Care Med. 2005; 172 (12): 1497–1504.
7. Colice G., Martin R.J., Israel E. et al. Asthma outcomes and costs of therapy with extrafine beclomethasone and fluticasone. J. Allergy Clin. Immunol. 2013; 132 (1): 45–54.
8. Zanen P., Go L.T., Lammers J.W. Optimal particle size for beta 2 agonist and anticholinergic aerosols in patients with severe airflow obstruction. Thorax. 1996; 51 (10): 977–980.
9. Criée C.P., Meyer T., Petro W. et al. In vitro comparison of two delivery devices for administering formoterol: Foradil P and formoterol ratiopharm single"dose capsule inhaler. J. Aerosol. Med. 2006; 19 (4): 466–472.
10. Colthorpe P., Voshaarb T., Kieckbusch T. et al. Delivery characteristics of a low"resistance dry"powder inhaler used to deliver the longacting muscarinic antagonist glycopyrronium. J. Drug Ass. 2013; 2: 11–16.
11. Chapman K.R., Fogarty C.M., Peckitt C. et al. Delivery characteristics and patients' handling of two single"dose dry"powder inhalers used in COPD. Int. J. Chron. Obstruct. Pulm. Dis. 2011; 6: 353–363.
12. Demoly P., Hagedoorn P., de Boer A.H., Frijlink H.W. The clinical relevance of dry powder inhaler performance for drug delivery. Respir. Med. 2014; 108 (8): 1195–1203.
13. Malmberg L.P., Rytilä P., Happonen P., Haahtela T. Inspiratory flows through dry powder inhaler in chronic obstructive pulmonary disease: age and gender rather than severity matters. Int. J. Chron. Obstruct. Pulm. Dis. 2010; 5: 257–262.
14. Weuthen T., Roeder S., Brand P. et al. In vitro testing of two formoterol dry powder inhalers at different flow rates. J. Aerosol. Med. 2002; 15 (3): 297–303.
15. Alaboud S.S. In"vitro inhalation performance for formoterol dry powder and metred dose inhalers. University of Bradford; 2011. https://bradscholars.brad.ac.uk/bitstream/handle/10454/5686/Final_Ph.D 12.4.2012pdf.pdf?sequence=1 Date last accessed: June 14, 2016.
16. Hamilton M., Leggett R., Pang C. et al. In vitro dosing performance of the ellipta dry powder inhaler using asthma and COPD patient inhalation profiles replicated with the electronic lung (eLung™). J. Aerosol. Med. Pulm. Drug Deliv. 2015; 28 (6): 498–506.
17. Ciciliani A., Wachtel H., Langguth P. Comparing Respimat® Soft Mist™ inhaler and DPI aerosol deposition by combined in vitro measurements and CFD simulations. Respir. Drug Delivery. 2014; 2: 453–456.
18. Newman S.P., Sutton D.J., Segarra R. et al. Lung deposition of aclidinium bromide from Genuair, a multidose dry powder inhaler. Respiration. 2009; 78 (3): 322–328.
19. Corradi M., Chrystyn H., Cosio B.G. et al. NEXThaler, an innovative dry powder inhaler delivering an extrafine fixed combination of beclometasone and formoterol to treat large and small airways in asthma. Exp. Opin. Drug Deliv. 2014; 11 (9): 1497–1506.
20. Scichilone N. Asthma control: the right inhaler for the right patient. Adv. Ther. 2015; 32 (4): 285–292.
21. Pasquali I. et al. Poster presentation at the 2012 AAPS Annual Meeting and Exposition, October 14–18, 2012; Chicago. Poster: M1150.
22. Newman S.P. Principles of metered"dose inhaler design. Respir. Care. 2005; 50 (9): 1177–1790.
23. Leach C.L., Davidson P.J., Boudreau R.J. Improved airway targeting with the CFC"free HFA"beclomethasone metereddose inhaler compared with CFC"beclomethasone. Eur. Respir. J. 1998; 12 (6): 1346–1353.
24. Hochrainer D., Hölz H., Kreher C. et al. Comparison of the aerosol velocity and spray duration of Respimat Soft Mist inhaler and pressurized metered dose inhalers. J. Aerosol. Med. 2005; 18 (3): 273–282.
25. Melani A.S., Bonavia M., Cilenti V. et al. Inhaler mishandling remains common in real life and is associated with reduced disease control. Respir. Med. 2011; 105 (6): 930–938.
26. Pitcairn G., Reader S., Pavia D., Newman S. Deposition of corticosteroid aerosol in the human lung by Respimat Soft Mist inhaler compared to deposition by metered dose inhaler or by Turbuhaler dry powder inhaler. J. Aerosol. Med. 2005; 18 (3): 264–272.
27. Ciciliani A., Wachtel H., Langguth P. Comparing Respimat Soft Mist inhaler and DPI aerosol deposition by combined in vitro measurements and CFD simulations. Respir. Drug Delivery. 2014; 2: 453–456.
28. Ciciliani A., Wachtel H., Heussel C., Langguth P. Evaluation of Respimat Soft Mist inhaler based on in vitro measurements and CFD simulations. Respir. Drug Delivery. 2015; 2: 357–362.
29. van Noord J.A., Cornelissen P.J., Aumann J.L. et al. The efficacy of tiotropium administered via Respimat Soft Mist inhaler or HandiHaler in COPD patients. Respir. Med. 2009; 103 (1): 22–29.
Review
For citations:
Arkhipov V.V., Arkhipova D.E., Lazareva N.B. Novel inhalation devices for treatment of chronic obstructive pulmonary disease. PULMONOLOGIYA. 2016;26(3):352-356. (In Russ.) https://doi.org/10.18093/0869-0189-2016-26-3-352-356
Views:
1162
Email this article 